98 a Randomised Phase Ii Trial of a Drug Eluting Bead in the Treatment of Hepatocellular Carcinoma by Transcatheter Arterial Chemoembolization

Doxorubicin‐eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma

“…) shows, bibliographic search yielded 18 relevant articles after exclusion of articles that did not deal with DEB‐TACE versus conventional TACE or did not report the specific results being evaluated in this review; no relevant studies were found through manual search. From these 18 articles, we retrieved 10 articles for further review and excluded eight articles because of insufficient data . As three articles (Vogl et al ., Lammer et al ., and Lencioni et al …”

First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI)

“…Assessment of tumour viability and tumour necrosis such as the mRECIST criteria in HCC (36) may provide a better assessment of treatment response. In our patients we were unable to measure tumour necrosis accurately.…”

Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis

“…Two recent trials presented at the American Society of Clinical Oncology annual Meeting 2009, one retrospective [18], and one prospective [19] have shown an advantage in terms of overall survival and objective complete responses in favor of pTACE with microspheres for patients with unresectable HCC.…”